nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRD1—forebrain—attention deficit hyperactivity disorder	0.0402	0.119	CbGeAlD
Naltrexone—OPRK1—forebrain—attention deficit hyperactivity disorder	0.0385	0.114	CbGeAlD
Naltrexone—OPRM1—forebrain—attention deficit hyperactivity disorder	0.0274	0.0814	CbGeAlD
Naltrexone—OPRD1—nervous system—attention deficit hyperactivity disorder	0.0218	0.0648	CbGeAlD
Naltrexone—OPRD1—central nervous system—attention deficit hyperactivity disorder	0.021	0.0624	CbGeAlD
Naltrexone—OPRK1—nervous system—attention deficit hyperactivity disorder	0.0209	0.0621	CbGeAlD
Naltrexone—OPRK1—central nervous system—attention deficit hyperactivity disorder	0.0201	0.0598	CbGeAlD
Naltrexone—OPRK1—cerebellum—attention deficit hyperactivity disorder	0.0197	0.0585	CbGeAlD
Naltrexone—OPRM1—midbrain—attention deficit hyperactivity disorder	0.0181	0.0538	CbGeAlD
Naltrexone—OPRD1—brain—attention deficit hyperactivity disorder	0.0167	0.0495	CbGeAlD
Naltrexone—OPRK1—brain—attention deficit hyperactivity disorder	0.016	0.0475	CbGeAlD
Naltrexone—OPRM1—nervous system—attention deficit hyperactivity disorder	0.0149	0.0442	CbGeAlD
Naltrexone—OPRM1—central nervous system—attention deficit hyperactivity disorder	0.0143	0.0426	CbGeAlD
Naltrexone—OPRM1—brain—attention deficit hyperactivity disorder	0.0114	0.0338	CbGeAlD
Naltrexone—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00791	0.0235	CbGeAlD
Naltrexone—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00669	0.0199	CbGeAlD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0065	0.0098	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00637	0.0096	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00635	0.00958	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00632	0.00953	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00622	0.00938	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00592	0.00893	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00557	0.0084	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00556	0.00838	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00549	0.00828	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00546	0.00823	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00543	0.00818	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00538	0.00811	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00534	0.00806	CbGpPWpGaD
Naltrexone—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00522	0.0155	CbGeAlD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00503	0.00759	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00489	0.00737	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00484	0.00729	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00476	0.00717	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00474	0.00715	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00474	0.00714	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00471	0.0071	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00461	0.00695	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00441	0.00666	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0044	0.00663	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00436	0.00657	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00431	0.0065	CbGpPWpGaD
Naltrexone—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00429	0.0127	CbGeAlD
Naltrexone—OPRD1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00427	0.00644	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00424	0.00639	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.0042	0.00633	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00416	0.00627	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00416	0.00626	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00414	0.00625	CbGpPWpGaD
Naltrexone—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00413	0.0123	CbGeAlD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00409	0.00617	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00408	0.00614	CbGpPWpGaD
Naltrexone—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00404	0.012	CbGeAlD
Naltrexone—OPRM1—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00402	0.00606	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.004	0.00603	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00396	0.00597	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00389	0.00587	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00386	0.00582	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00386	0.00582	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00385	0.0058	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00378	0.0057	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00377	0.00568	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00374	0.00564	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00373	0.00562	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0037	0.00558	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00368	0.00555	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00363	0.00548	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00359	0.00541	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00358	0.0054	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00358	0.0054	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00357	0.00539	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00351	0.0053	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00351	0.00529	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00351	0.00528	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00347	0.00524	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00342	0.00515	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00339	0.00512	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00339	0.0051	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00337	0.00508	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00334	0.00503	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00331	0.00498	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.0033	0.00497	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00328	0.00495	CbGpPWpGaD
Naltrexone—ABCB1—brain—attention deficit hyperactivity disorder	0.00328	0.00975	CbGeAlD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00326	0.00492	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00325	0.0049	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00325	0.00489	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00323	0.00487	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00321	0.00483	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0032	0.00482	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00316	0.00477	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00314	0.00474	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00311	0.00469	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00307	0.00463	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00307	0.00463	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00307	0.00463	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00303	0.00457	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00302	0.00455	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00298	0.00449	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00294	0.00443	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00293	0.00441	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00289	0.00436	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00289	0.00435	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00288	0.00434	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00287	0.00433	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00286	0.00431	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00285	0.0043	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00279	0.00421	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00274	0.00413	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00273	0.00412	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00269	0.00406	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00268	0.00404	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00267	0.00402	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00266	0.004	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0026	0.00392	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00259	0.0039	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00254	0.00383	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00252	0.0038	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00252	0.00379	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00251	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00251	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00248	0.00374	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00247	0.00373	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00244	0.00368	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00243	0.00367	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00243	0.00367	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0024	0.00361	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00235	0.00354	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00234	0.00353	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00234	0.00352	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00228	0.00343	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00227	0.00342	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00223	0.00336	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.0022	0.00332	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.0022	0.00332	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00219	0.0033	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00218	0.00328	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00215	0.00324	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00213	0.00321	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00213	0.00321	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00205	0.00309	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00203	0.00305	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00198	0.00299	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00198	0.00298	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00192	0.00289	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00192	0.00289	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00189	0.00284	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00188	0.00284	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00186	0.0028	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00186	0.0028	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00186	0.0028	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00184	0.00277	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00184	0.00277	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0018	0.00272	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00176	0.00265	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00173	0.00261	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00171	0.00257	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00169	0.00254	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00164	0.00247	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00163	0.00245	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00162	0.00245	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00162	0.00244	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00159	0.0024	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00151	0.00227	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0015	0.00226	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00148	0.00223	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00147	0.00222	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00147	0.00221	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00146	0.0022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00144	0.00217	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00216	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00144	0.00216	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00142	0.00214	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00142	0.00214	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00141	0.00212	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00138	0.00207	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00138	0.00207	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00137	0.00206	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00133	0.002	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00133	0.002	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00132	0.00199	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00132	0.00199	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00131	0.00198	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.0013	0.00197	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00129	0.00195	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00129	0.00194	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00129	0.00194	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00128	0.00193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00126	0.00191	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00126	0.0019	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00126	0.0019	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00125	0.00188	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00124	0.00187	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00124	0.00186	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00121	0.00183	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.0012	0.00181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0012	0.00181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.0012	0.00181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00116	0.00175	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00116	0.00175	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00114	0.00172	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00113	0.0017	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00112	0.00169	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00109	0.00165	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00109	0.00164	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00108	0.00163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00106	0.00161	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00106	0.0016	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00105	0.00159	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00105	0.00158	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00104	0.00157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00102	0.00153	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000996	0.0015	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000983	0.00148	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000979	0.00148	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000966	0.00146	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000954	0.00144	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000925	0.00139	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000917	0.00138	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000917	0.00138	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000903	0.00136	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000889	0.00134	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000873	0.00132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00087	0.00131	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00084	0.00127	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000839	0.00126	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000811	0.00122	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000809	0.00122	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000784	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00077	0.00116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000763	0.00115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000761	0.00115	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000738	0.00111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000737	0.00111	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000733	0.00111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00071	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000709	0.00107	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000698	0.00105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000687	0.00104	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000686	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000675	0.00102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000667	0.00101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000645	0.000972	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00064	0.000965	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000623	0.000939	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000621	0.000937	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00061	0.000919	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.0006	0.000904	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000588	0.000886	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000581	0.000876	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000571	0.000861	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000564	0.00085	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000556	0.000838	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000552	0.000832	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000525	0.000792	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000496	0.000748	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000435	0.000656	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000421	0.000634	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000421	0.000634	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000414	0.000624	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000385	0.00058	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000368	0.000555	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000336	0.000507	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00032	0.000483	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000263	0.000396	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000255	0.000384	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000253	0.000382	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000238	0.000359	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000231	0.000348	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000195	0.000294	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000109	0.000165	CbGpPWpGaD
